Cystic Fibrosis Nursing Care Plans

Cystic fibrosis patients live with thick, dehydrated mucus that plugs the airways and a pancreas that cannot get enzymes to the gut. On the unit your work comes down to four jobs: keep airways clear, catch exacerbations early, protect the patient from cross-infection, and keep calories going in. Everything below serves those jobs.

What is Cystic Fibrosis?

CF is an autosomal recessive disorder. Both parents carry a mutated gene for the cystic fibrosis transmembrane conductance regulator (CFTR), a protein in mucus-secreting cells. The defect disrupts chloride movement, which thickens exocrine secretions and dumps electrolytes into sweat. It hits the respiratory, gastrointestinal, and reproductive tracts.

The hallmark is chronic, progressive lung disease from dehydrated mucus and airway obstruction, plus malnutrition from pancreatic insufficiency. Severity varies widely. Pulmonary disease ranges from nearly asymptomatic to severe obstruction in early childhood. GI disease ranges from mild constipation and intermittent pancreatitis to full pancreatic failure, malabsorption, CF-related diabetes, and end-stage liver disease. Reproductive glands are affected too: nearly all males are sterile from an absent or impaired vas deferens, and females have reduced fertility.

Newborn screening runs in all US states and the District of Columbia. Sweat chloride analysis remains the gold standard for diagnosis, since the sweat glands secrete abnormally high chloride.

Nursing Care Plans & Management

You help the patient clear secretions with chest physiotherapy and breathing techniques, prevent and recognize respiratory infections, and keep fluid and nutrition adequate enough to support both secretion clearance and growth. CF is lifelong, so the plan adapts as the disease progresses. Raise palliative and end-of-life discussions when the trajectory calls for them, and support the family through a shortened, uncertain lifespan.

Nursing Problem Priorities

• Airway obstruction and inflammation
• Decreased respiratory function
• Chronic lung infection and complications
• Malabsorption and nutritional deficiency
• Exacerbations and hospitalizations
• Education and knowledge gaps
• Unrealistic expectations and emotional strain
• Family stress and support exhaustion

Nursing Assessment

CF shows up as a productive cough, wheezing, hyperinflation on chest x-ray, and obstructive airway disease. Impaired mucus clearance drives chronic inflammation and infection, with early colonization by S. aureus and H. influenzae and later P. aeruginosa. Expect upper-airway involvement too (sinusitis, nasal polyps), plus the nonpulmonary picture: GI disease, CF-related diabetes, and fertility problems.

Assess for the following subjective and objective data:

• Cough, wheezing, dyspnea
• Hypercapnia and hypoxemia
• Pale or cyanotic skin, restlessness
• Tachypnea, tachycardia, labored breathing
• Abnormal chest x-ray; declining spirometry
• Chest pain, fatigue, reduced breath sounds
• Crackles and rhonchi
• Abnormal eating behaviors
• GI abnormalities (recurrent pancreatitis, biliary cirrhosis)

Assess for factors related to the cause of CF:

• Airway obstruction and alveolar inflammation
• Bronchiectasis with lost surface area for gas exchange
• Infection with consolidation and alveolar collapse
• Increased mucopurulent secretions and mucous plugging from new or growing airway bacteria
• Acquisition of known CF airway pathogens or a viral organism
• Chronic malabsorption, increased caloric needs, anorexia
• First exacerbation or hospitalization
• Incomplete prior education; a fast-changing treatment landscape
• Unrealistic expectations
• Family disorganization, role changes, and exhausted caregiver capacity

Nursing Diagnosis

Formulate the diagnosis from your assessment and clinical judgment, matched to this patient's airway, nutritional, and family picture. The interventions below stand on their own regardless of the diagnostic label you use.

Nursing Goals

The patient will maintain optimal gas exchange, shown by oxygen saturation of 90% or greater, ABGs within their usual range, relaxed breathing, baseline heart rate, and alert mentation with no further decline in consciousness. They will understand the causes and treatments and take part in the regimen within their abilities. They will clear secretions daily with effective airway clearance therapy, shown by decreased work of breathing and improved pulmonary function, and keep a clear airway with normal breath sounds and an effective cough. They will show improvement in infection and suppression of bacterial growth, shown by decreased cough, mucus production back to baseline, normothermia, and a normal white blood cell count.

Nursing Interventions and Actions

1. Maintaining Patent Airways & Improving Gas Exchange

Thick mucus obstructs the airways and impairs breathing. Use airway clearance techniques, bronchodilators, and mucolytics to mobilize secretions, open the airways, and protect gas exchange.

1. Monitor vital signs, especially respiratory and heart rate. Both rise to compensate for early hypoxia. Watch also for chest retractions, increased work of breathing, nasal flaring, and accessory muscle use. These signal respiratory distress and need prompt treatment.

2. Assess the cough for effectiveness. Cough is both a symptom and the patient's main airway defense. Many CF patients habitually suppress it, which retains mucus, but an excessive cough can collapse airways without clearing them. Effective, intentional coughing is what clears secretions.

3. Assess for changes in respiratory status: cyanosis, pallor, altered consciousness, labored breathing, tachypnea. The patient adapts their breathing pattern over time to keep gas exchange going, so any abnormality points to compromise, hypercarbia, or hypoxia. A child with CF often shows a barrel chest (anterior-posterior diameter approaching the transverse) and nail bed clubbing from chronic hypoxia.

4. Assess sputum for color, amount, and consistency. Less sputum, lighter color, and thinner consistency mean the exacerbation is improving. Scant blood streaking can come from airway inflammation, but major hemoptysis is a life-threatening emergency.

5. Assess the chest wall for even expansion. Unequal expansion can mean pneumothorax, a CF complication. Over time the chest takes on a barrel shape with increased front-to-back diameter.

6. Monitor transcutaneous carbon dioxide as ordered. Chronic hypercarbia appears in moderate to severe CF lung disease, and rising levels can signal a progressing infection and pending respiratory failure. Like hypoxemia, it carries mortality risk and is an indication for lung transplant referral. Screen patients with advanced cystic fibrosis lung disease (ACFLD) annually for hypercarbia using a venous blood gas.

7. Monitor arterial blood gases and oxygen saturation as indicated. Rising PaCO2 and falling PaO2 signal respiratory failure; severe hypoxemia and hypercarbia can cause hypotension, dysrhythmias, and failing respiratory effort. Per Medicare and most third-party payer requirements, if venous PaCO2 is >56 mm Hg, obtain a confirmatory arterial blood gas.

8. Auscultate breath sounds and percuss for resonance. Expect fine or coarse crackles and scattered or localized wheezing. With progressive obstruction, breath sounds diminish, and percussion over the lung fields yields hyperresonance from air trapping.

9. Assess comfort with and adherence to the chosen airway clearance therapy (ACT). Satisfaction and proficiency drive adherence. Patients who feel an activity worsens their cough tend to skip it, and poor adherence carries serious consequences.

10. Assess for barriers to ongoing airway clearance. Identifying barriers lets you target them. Common ones are interruptions to daily life, sleeping late, time pressure, and discomfort about doing treatments in front of others. ACT and nebulizer treatments are often the hardest parts of self-care for patients and families.

11. Assess mental status and general appearance. Restlessness, irritability, confusion, and somnolence may reflect hypoxemia or reduced cerebral oxygenation. The patient may tire and become irritable, with a gradual change in appearance.

12. Monitor pulmonary function testing. Improving spirometry signals better airflow, effective clearance, and treated infection. Early on, FEV1 may be normal while forced expiratory flow after 25% to 75% of vital capacity is reduced, pointing to small airway involvement.

13. Provide opportunities for exercise and physical therapy. Exercise loosens mucus, supports effective coughing, and builds overall conditioning. Upper-body work such as canoe paddling can increase respiratory muscle endurance.

14. Teach breathing techniques. Active breathing exercises, often paired with airway clearance devices, strengthen lung capacity and clear mucus. Demonstrate the technique and device together so the patient can build a daily clearance routine.

15. Provide rest between daytime activities and protect nighttime sleep. Pace activity to limit oxygen demand and fatigue. CF predisposes patients to hypoxemia, which disrupts sleep and causes daytime impairment.

16. Position in semi-Fowler's or elevate the head of the bed. This promotes lung expansion, reduces airway collapse and work of breathing through gravity, and improves expectoration.

17. Encourage frequent, effective coughing, especially around ACT. Habitual suppression retains mucus. Active coughing combined with changes in body position recruits poorly ventilated lung zones.

18. Use play therapy to teach coughing and breathing to younger children. Children younger than 7 years cannot voluntarily produce an effective cough. Make it a game: when using a spirometer, have the child "blow up" the fingers of a clean glove.

19. Assist with chest physiotherapy as appropriate. For CF this is a critical intervention, not just an adjunct. Percussion, vibration, and postural drainage, or another bronchial hygiene therapy, must run several times a day to mobilize secretions.

20. Administer hypertonic saline by nebulizer. Hypertonic saline hydrates the airway surface liquid without worsening bacterial infection or inflammation. For patients 6 years or older, long-term 7% hypertonic saline (4 mL by nebulizer twice daily) improves lung function and reduces exacerbations compared with normal saline.

21. Administer oxygen as indicated, avoiding high concentrations in chronic CO2 retainers. Supplemental oxygen maintains oxygenation, reduces work of breathing and calorie expenditure, and relieves dyspnea; keep saturation above 90%. Nocturnal and exertional oxygen improve oxygenation with possible slight worsening of hypercarbia, and in ACFLD they improve exercise capacity and reduce school or work absence.

22. Collaborate with respiratory care on noninvasive ventilation as indicated. Bilevel positive airway pressure suits severe lung disease with a superimposed acute illness or nighttime ventilatory needs. Nocturnal NIV for hypercarbia improves PaCO2, dyspnea, and exercise tolerance and can bridge a patient to transplant.

23. Promote pulmonary rehabilitation. Strength and aerobic training improve exercise capacity and quality of life, and some programs slow the decline in lung function. Rehab also helps prepare for lung transplant and is required by some transplant programs.

24. Prepare for ICU transfer if indicated. Survival after ICU admission has improved. Survival to discharge runs as high as 55% when transplant is an option and 10% to 55% when it is not. Patients with ACFLD and acute respiratory failure should be considered eligible for ICU care regardless of transplant status when it fits their goals of care.

25. Administer humidified oxygen as ordered. Humidification thins and loosens secretions. In chronic obstructive disease the respiratory center tolerates low oxygen saturation, so high oxygen concentrations can trigger carbon dioxide narcosis.

26. Administer intermittent aerosol therapy as appropriate. Aerosols deliver medication to the lower airways and promote secretion clearance. A single daily aerosol dose of recombinant human deoxyribonuclease (dornase alfa) thins secretions and improves pulmonary function.

27. Choose the ACT method with the patient and team. Options include autogenic or postural drainage, handheld oscillating devices, mechanical chest wall percussion (vest), or traditional chest physiotherapy. CF secretions are thick and sticky, so frequent clearance is a mainstay of both exacerbation treatment and maintenance. Patient choice drives adherence; involve a respiratory therapist.

28. Schedule ACT so it fits the rest of the plan. ACT is time-consuming. Keep it away from meals and away from rest, medications, and physical therapy, which takes careful scheduling.

29. Assist in preparing for lung transplant as appropriate. ACFLD remains the most common cause of death in CF and carries significant morbidity. Transplant improves quality of life and survival, with the biggest benefit in the severely impaired who carry additional predictors of mortality.

30. Administer medications as prescribed. See Pharmacologic Management below.

2. Administering Medications and Pharmacological Support

CF medications target digestion, airway function, and infection.

1. Pancreatic enzyme replacement therapy (PERT). Agents such as pancrelipase supply the digestive enzymes a patient with pancreatic insufficiency lacks, so they can break down and absorb fats, proteins, and carbohydrates.

2. Bronchodilators. Albuterol or salbutamol relax airway smooth muscle to open the airways and improve airflow, given by inhaler or nebulizer.

3. Mucolytics. Dornase alfa thins the thick airway mucus, lowering viscosity to improve clearance and lung function.

4. Inhaled antibiotics. Tobramycin or colistimethate sodium deliver antibiotic directly to the lungs to control the bacteria that cause chronic CF lung infection.

5. CFTR modulators. Ivacaftor, lumacaftor, and tezacaftor target specific CFTR defects to improve the protein's function and address the underlying disease.

6. Anti-inflammatory medications. Corticosteroids, oral or inhaled, may reduce airway inflammation and control symptoms in selected patients.

7. Proton pump inhibitors (PPIs). Omeprazole or lansoprazole reduce stomach acid in patients with GERD, easing reflux symptoms and protecting the esophagus.

3. Monitoring Diagnostic Procedures and Laboratory Studies

Regular monitoring lets you adjust therapy and act early on exacerbations and complications.

1. Sweat test. Measures chloride and sodium in sweat; elevated chloride indicates CF.

2. Genetic testing. Identifies CFTR mutations to confirm CF, whether through newborn screening or workup of a suspected case.

3. Pulmonary function tests. Spirometry and lung volumes assess airflow limitation and lung capacity, reporting FEV1 and forced vital capacity (FVC).

4. Chest x-ray. Shows structural changes such as infection, bronchiectasis, or lung damage.

5. Sputum culture. Identifies the bacteria or fungi driving infection and guides antibiotic choice.

6. Blood tests. Track liver function, pancreatic enzymes, electrolytes, and inflammatory markers to catch complications.

7. Nasal potential difference. Measures electrical activity across the nasal lining to assess CFTR function and confirm CF in selected cases.

4. Promoting Infection Control & Management

Thick secretions obstruct the airways and pool, creating a breeding ground for bacteria that leads to bronchiectasis, atelectasis, and hyperinflation. Tight infection control across the team protects the patient and the wider CF community.

1. Assess for signs of infection: fever, cough, malaise, increased sputum, weight loss, tachypnea, tachycardia. Pulmonary infection raises respiratory and heart rate. The cough may start dry and hacking and progress to mucoid then purulent sputum; infants can show prolonged bronchiolitis.

2. Obtain a sputum culture and sensitivity as ordered. New pathogens often drive exacerbations. Common CF pathogens include Staphylococcus aureus, Pseudomonas aeruginosa, MRSA, Achromobacter xylosoxidans, Burkholderia cepacia, and Stenotrophomonas maltophilia. Cultures guide both infection control and antimicrobial choice.

3. Monitor oxygen saturation. Oxygen needs rise during acute infection or fever, and pulse oximetry catches impaired saturation early.

4. Monitor immunoglobulin E (IgE) as ordered. Allergic bronchopulmonary aspergillosis (ABPA), an allergic response to Aspergillus in the airways, can drive exacerbations and markedly elevates IgE.

5. Monitor culture and sensitivity results for drug resistance. Resistance may force an antibiotic change, and a new organism may change isolation precautions. MRSA colonization and infection are critical factors in CF lung infection and function, and patients may need multiple regimens.

6. Monitor viral studies as ordered. Exacerbations often follow or coincide with viral illness. CF patients get frequent infections with RSV, rhinovirus, influenza, parainfluenza, and adenovirus; RSV and influenza cause the largest drops in lung function.

7. Monitor the white blood cell count as ordered. WBC can rise with exacerbation or a new organism. Viral infection weakens antibacterial defenses such as phagocyte recruitment and antimicrobial peptide production, raising the risk of bacterial infection.

8. Monitor antibiotic levels as ordered. Underdosing breeds resistance and poor response; toxicity causes adverse events. Regimens range from a short single-agent course to prolonged multidrug therapy by oral, IV, or inhaled routes.

9. Enforce strict hand hygiene and asepsis for all staff, caregivers, and the patient. CF patients have low resistance to respiratory infection. Handwashing is the first line of defense; teach it to the family and follow medical asepsis with both the patient and the equipment.

10. Do not cohort CF patients. CF Infection Control Consensus Guidelines advise against cohorting. Keep the patient away from others who may carry infection and keep the hospital stay brief to avoid cross-infection.

11. Teach proper disposal of infectious waste, especially secretions. Patients may find expectoration offensive and limit it, but sputum must be disposed of safely to avoid contaminating staff or caregivers.

12. Administer antipyretics as ordered, avoiding NSAIDs in patients on IV aminoglycosides. Antipyretics maintain normothermia and lower metabolic demand. Aminoglycosides plus NSAIDs can cause renal toxicity. Anti-inflammatories such as ibuprofen have a growing role in CF, but watch closely for adverse effects like GI bleeding.

13. Administer IV antibiotics promptly. Benchmark institutions give the first IV dose within 4 hours of admission. Once-daily aminoglycoside dosing shows no significant difference from thrice-daily dosing in lung function, weight for height, or BMI, and creatinine changes favor once-daily dosing in children, supporting the move to once-daily IV aminoglycosides.

14. Consider audiology evaluation in patients with frequent IV aminoglycoside use. Ototoxicity is a common aminoglycoside effect, reported in 2% to 45% of adults, and can be vestibular or cochlear and dose-dependent. Serial audiometry can catch irreversible hearing loss early.

15. Institute the appropriate infection control precautions. Many CF pathogens require contact isolation per CDC and CF Foundation guidelines. Apply the "6-foot rule": CF patients stay at least 6 feet from each other in all settings, and household members stay 6 feet from anyone with a respiratory infection. CF patients also avoid communal areas like playrooms or the gym at the same time as others.

16. Administer routine vaccinations as indicated, including seasonal influenza. Routine immunizations are indicated in CF. Evidence for the palivizumab vaccine against RSV in CF is limited; a randomized trial showed no increase in adverse events and no measurable benefit.

5. Promoting Optimal Nutrition

Good nutrition supports lung function and treatment response. Build an individualized plan with a dietitian based on age, disease severity, growth, and metabolic demand.

1. Assess the abdomen for bloating, fullness, bowel sounds, or a palpable stool mass. Undertreated malabsorption is common and often normalized by patients and families. Adjust enzyme supplementation when malabsorption appears. Abnormal motility can contribute to meconium ileus, and distention can be severe enough to cause respiratory distress.

2. Monitor stool patterns: frequency, odor, consistency, oil or grease. Increased frequency suggests malabsorption, failure to thrive, intussusception, or rectal prolapse. Malabsorption produces steatorrhea: frequent, poorly formed, bulky, foul-smelling, greasy stools that float.

3. Assess skin color, integrity, and turgor. Malnutrition impairs skin integrity, and CF-related liver disease causes jaundice. Sodium and chloride loss in sweat leaves a salty skin surface and predisposes the patient to electrolyte imbalance in hot weather.

4. Monitor weight and appetite. Rising weight and appetite track with resolving exacerbations. Increased energy demand, malabsorption, and anorexia together cause poor weight gain.

5. Monitor for excessive thirst, urination, and hunger; obtain bedside glucose as ordered. CF-related diabetes occurs in up to 30% of adolescents and adults, and glucose intolerance can come and go with exacerbations. Thick secretions damage the exocrine pancreas, and progressive fibrosis destroys islet architecture, reducing insulin-producing cells.

6. Monitor serum chemistry as ordered. Hypoalbuminemia, elevated liver enzymes, hyperglycemia, and electrolyte shifts all signal complications. Albumin is the major protein in meconium with meconium ileus and runs 5 to 10 times higher than normal, with increased glutamyl transpeptidase (GGTP) and 5-nucleotidase that promote meconium ileus.

7. Determine the patient's usual feeding pattern, food likes and dislikes, and activity level. This shapes a feasible feeding plan. In children, base energy requirements on growth and weight gain.

8. Observe for muscle wasting and loss of subcutaneous fat. Thickened secretions block pancreatic enzyme flow, so fats and proteins go undigested. The patient fails to gain weight despite a good appetite and looks undernourished, with wasting of the buttocks and thighs as fat disappears.

9. Encourage liberal hydration and high fiber. Mucus and intestinal dehydration cause chronic constipation, especially once malabsorption is treated and stools normalize. Soluble fiber softens stool; a child's daily fiber in grams should equal their age plus 5, to a maximum of 25 g per day.

10. Encourage liberal salt or salty foods. Hyponatremic dehydration and salt loss come easily from CF sweat gland defects. Add salt for patients in hot climates, especially during exercise or heavy sweating.

11. Encourage a high-protein, high-calorie diet. CF raises caloric needs to 1.2 to 1.5 times the recommended amount. Continue breastfeeding with enzyme supplementation as long as possible, supplementing with higher-calorie formula when needed; a partially hydrolyzed formula with medium-chain triglycerides may help.

12. Give fat-soluble vitamins with meals and enzymes. Fat malabsorption causes deficits in vitamins A, D, E, and K. Give water-miscible forms with pancreatic enzymes and multivitamins; add extra enzymes with high-fat foods.

13. Administer pancreatic enzymes with all meals and snacks containing fat or protein as ordered. Enzyme replacement is the main treatment for pancreatic insufficiency, taken with food so enzymes mix in the duodenum. Swallow capsules whole or sprinkle the contents on a small amount of food at the start of the meal; do not crush or chew them.

14. Collaborate with a registered dietitian for a full nutritional evaluation. Most CF patients carry a long history of impaired nutrition, so guide interventions with baseline data and multidisciplinary input.

15. Assist with nasogastric or gastrostomy tube placement and feedings. High-energy oral preparations or enteral feeds may be needed. Gastrostomy tube placement improves BMI percentile and percent-predicted FEV1 in male patients and female pediatric patients.

6. Promoting Effective Family Coping

Successful coping depends on the patient, the family, and the support around them. Coordinate across the team to meet each family's needs.

1. Determine family and caregiver involvement and availability. Treatments several times a day strain the whole family. Children often resist, leaving parents to enforce adherence, and parenting a child with CF means reshaping daily life around the disease.

2. Evaluate caregiver coping, especially before discharge. Chronic illness places a heavy strain on the family. Naming their strengths and growth areas builds the odds of success when the patient goes home.

3. Assess available community support and its use. Parents carry a double burden: disease progression, disrupted plans, outpatient visits, hospitalizations, complex regimens, and the financial cost of treatment.

4. Assess family and caregiver stress. The treatment routine can breed resentment in both child and family, and stress grows as the disease progresses. Make families aware of counseling resources.

5. Encourage the family and patient to express their feelings, and listen. A family facing a long-term illness may have already seen the child decline. Let them voice fears and anxieties, use active listening to validate them, and provide emotional support throughout the stay without signaling that they are intruding on your time.

6. Encourage caregivers to take part in care at their level of desire and ability, within safety limits. Participation helps the family feel supported and connected. Family-centered care reduces the long-term impact of poor family functioning.

7. Accept the family's choices about their level of involvement. Families may withdraw or project guilt by criticizing staff. When possible, offer trusted respite care so parents can step away briefly without undue worry.

8. Support the family with attention, compassion, time, respect, honesty, advocacy, and understanding. Prepare caregivers for what they face. Active coping styles, such as acceptance, seeking social support, and planning, predict better quality of life and self-management for patients and families.

9. Inform the family of available services. Connect families to special child health services, local clinics, private agencies, and service clubs that provide equipment and medication free or at reduced cost.

10. Educate the patient and family about home care. The core of home teaching is mucus removal and breathing exercises. The program works only if these treatments are done faithfully as prescribed.

11. Encourage personal practices that build resilience. Spiritual coping, meditation, and meditative movement help. Spiritual belief can frame meaning, build social support and belonging, and serve as a coping strategy for chronic illness.

12. Encourage adolescents and young adults to strengthen self-management. Push personal ownership of the illness to maximize independence. Many young people with CF attend college or vocational training and complete degrees in person or by distance learning; encourage them to set goals and live as normally as the illness allows.

7. Providing Patient Education & Health Teachings

CF education spans lung health, nutrition, treatment, and genetics, for both patients and caregivers.

1. Assess baseline knowledge of the disease. CF affects the secretory glands and many organs, especially the lungs and pancreas. Patients and families often lack a full grasp of the genetics, the reproductive implications, and the effects outside the lungs.

2. Assess knowledge of nutritional needs. Understanding nutrition supports self-management. Adolescents often score lowest in the nutrition domain despite reporting confidence, partly from unfamiliar terminology, so teach the terms used by nutritionists and found on food labels.

3. Assess knowledge of infection control. Patients need a solid grasp of infection prevention to protect themselves and the CF community. Pulmonary disease is the most common cause of death in CF, so keep a low threshold for diagnosing and treating exacerbations.

4. Assess knowledge of CF genetics. CF comes from a defect in the CFTR gene, which controls salt and water movement in and out of cells. A child who inherits a defective CFTR gene from each parent will have CF.

5. Assess knowledge of medications, airway clearance, and equipment. Complex regimens are hard to maintain, and regular review finds gaps and sources of nonadherence. Life expectancy has risen sharply, with median predicted survival now around 65 years, so educate the patient as well as the caregivers.

6. Assess knowledge of diagnostic testing, including labs, spirometry, airway cultures, and pathogens. Knowing their baseline lung function and usual pathogens helps patients understand treatment goals. Low adherence drives reduced lung function, more exacerbations, longer hospital stays, and higher cost.

7. Provide basic CF pathophysiology and treatment goals from reliable resources. There is no cure. Treatment aims to prevent lung infection, clear mucus, prevent intestinal blockage, improve nutrition, and reduce dehydration. With careful self-management many patients now live into their 50s and 60s. Adults report their highest unmet needs as coping with decreased energy, future unpredictability, disease changes, and new therapies and side effects.

8. Provide information about support groups. Chronic illness is emotionally hard, and shared-experience groups help. Local agencies and community groups may also offer support.

9. Review pulmonary function testing and individual trends. Trends guide whether the disease is progressing or improving. The forced oscillation technique works in younger children; standard spirometry may not be reliable until 5 or 6 years, though some younger patients learn reproducible maneuvers.

10. Review ACT and breathing techniques. Chest physiotherapy is a mainstay, and patients often struggle with it, so discuss strategies and aids. ACT includes percussion and postural drainage, positive expiratory pressure (PEP), active-cycle breathing, autogenic drainage, oscillatory PEP, high-frequency chest compressions, and exercise; assess individually to find the best fit.

11. Review infection control recommendations. Patients and families need infection control strategies to prevent new pathogen acquisition. Keep the patient away from others who may carry infection, keep hospital stays brief, and give the necessary childhood immunizations.

12. Review pulmonary and nutritional or digestive medications and their rationales. Regimens change over time, so frequent review clarifies purpose and supports adherence. Pulmonary medications include antibiotics, bronchodilators, anti-inflammatories, and mucus thinners; nutritional medications include pancreatic enzymes, vitamins, and salt.

13. Provide reliable, accessible education resources. Time spent teaching matters even under time pressure. Direct patients to vetted national websites alongside brief, clinic-specific materials.

14. Teach pancreatic enzyme administration. Usually 1 to 5 capsules are taken with a meal and a smaller amount with snacks. Do not chew or crush the enteric-coated beads, since that inactivates the enzymes and can excoriate the oral mucosa. The powder form, used with infants and young children, must be handled carefully: inhaling it can trigger acute bronchospasm, and mixing it with food predigests the food and makes it unpalatable. Rinse the mouth after dosing to protect the oral mucosa or a breastfeeding mother's nipples.